471 related articles for article (PubMed ID: 17675394)
1. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
Goldhirsch A; Wood WC; Gelber RD; Coates AS; Thürlimann B; Senn HJ;
Ann Oncol; 2007 Jul; 18(7):1133-44. PubMed ID: 17675394
[TBL] [Abstract][Full Text] [Related]
2. Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Coates AS; Winer EP; Goldhirsch A; Gelber RD; Gnant M; Piccart-Gebhart M; Thürlimann B; Senn HJ;
Ann Oncol; 2015 Aug; 26(8):1533-46. PubMed ID: 25939896
[TBL] [Abstract][Full Text] [Related]
3. [Trend to adjuvant systemic treatment regimens for patients with early breast cancer--meeting highlights of St. Gallen Conference 2005].
Taguchi T
Gan To Kagaku Ryoho; 2006 May; 33(5):567-83. PubMed ID: 16685151
[TBL] [Abstract][Full Text] [Related]
4. Extended adjuvant chemotherapy in endocrine non-responsive disease.
Colleoni M; Munzone E
Breast; 2013 Aug; 22 Suppl 2():S161-4. PubMed ID: 24074780
[TBL] [Abstract][Full Text] [Related]
5. Hormone receptor-positive early breast cancer: controversies in the use of adjuvant chemotherapy.
Montemurro F; Aglietta M
Endocr Relat Cancer; 2009 Dec; 16(4):1091-102. PubMed ID: 19726539
[TBL] [Abstract][Full Text] [Related]
6. St. Gallen endocrine response classes predict recurrence rates over time.
Koornstra RH; Beelen KJ; Vincent AD; van der Noort V; van Diest PJ; Linn SC
Breast; 2015 Dec; 24(6):705-12. PubMed ID: 26429398
[TBL] [Abstract][Full Text] [Related]
7. First--select the target: better choice of adjuvant treatments for breast cancer patients.
Goldhirsch A; Coates AS; Gelber RD; Glick JH; Thürlimann B; Senn HJ;
Ann Oncol; 2006 Dec; 17(12):1772-6. PubMed ID: 17071934
[TBL] [Abstract][Full Text] [Related]
8. Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.
Senn HJ; Thürlimann B; Goldhirsch A; Wood WC; Gelber RD; Coates AS
Breast; 2003 Dec; 12(6):569-82. PubMed ID: 14659136
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy in luminal breast cancers.
Lim E; Winer EP
Breast; 2011 Oct; 20 Suppl 3():S128-31. PubMed ID: 22015279
[TBL] [Abstract][Full Text] [Related]
10. [Adjuvant chemotherapy of early stage breast cancer].
Boér K
Orv Hetil; 2010 Feb; 151(9):344-53. PubMed ID: 20159750
[TBL] [Abstract][Full Text] [Related]
11. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
Goldhirsch A; Glick JH; Gelber RD; Coates AS; Thürlimann B; Senn HJ;
Ann Oncol; 2005 Oct; 16(10):1569-83. PubMed ID: 16148022
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
13. Traditional molecular markers and response to adjuvant endocrine or trastuzumab-based therapies.
Viale G; Ghioni M; Mastropasqua MG
Curr Opin Oncol; 2010 Nov; 22(6):541-6. PubMed ID: 20827197
[TBL] [Abstract][Full Text] [Related]
14. [Adjuvant chemotherapy in primary carcinoma of the breast].
Harbeck N
Zentralbl Gynakol; 2003 Sep; 125(9):322-6. PubMed ID: 14569511
[TBL] [Abstract][Full Text] [Related]
15. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
16. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
17. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
Goldhirsch A; Ingle JN; Gelber RD; Coates AS; Thürlimann B; Senn HJ;
Ann Oncol; 2009 Aug; 20(8):1319-29. PubMed ID: 19535820
[TBL] [Abstract][Full Text] [Related]
18. Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011.
Goldhirsch A; Wood WC; Coates AS; Gelber RD; Thürlimann B; Senn HJ;
Ann Oncol; 2011 Aug; 22(8):1736-47. PubMed ID: 21709140
[TBL] [Abstract][Full Text] [Related]
19. The curability of breast cancer and the treatment of advanced disease.
Guarneri V; Conte PF
Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
[TBL] [Abstract][Full Text] [Related]
20. Optimal indications of endocrine therapy alone as adjuvant systemic treatment of breast cancer.
Horii R; Akiyama F; Ito Y; Iwase T
Br J Cancer; 2007 Sep; 97(5):654-8. PubMed ID: 17726451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
